B of A Securities Maintains Buy on AVITA Medical, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Lyanne Harrison maintains a 'Buy' rating on AVITA Medical (NASDAQ:RCEL) and raises the price target from $18 to $27.
July 28, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities maintains a 'Buy' rating on AVITA Medical and raises the price target from $18 to $27.
The raised price target by B of A Securities indicates a positive outlook for AVITA Medical. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100